Investor Presentaiton

Company overview Financial performance Oncology Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Ophthalmology Neuroscience Respiratory Disease icenticaftor - CFTR potentiator NCT04072887 (CQBW251B2201) Chronic obstructive pulmonary disease Indication Phase Phase 2 Patients 956 Primary Outcome Measures Arms QBW251 450 mg Intervention QBW251 300 mg Trough FEV1 (Forced Expiratory Volume in 1 second) change from baseline after 12 weeks of treatment Target Patients QBW251 150 mg QBW251 75 mg QBW251 25 mg Placebo COPD patients on background triple inhaled therapy (LABA / LAMA / ICS) Read-out Milestone(s) Q2-2022 (actual) Publication Primary publications planned H2 2022 89 Investor Relations | Q2 2022 Results References Abbreviations Cardio-Renal Global Health Biosimilars NOVARTIS | Reimagining Medicine

View entire presentation